<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161731</url>
  </required_header>
  <id_info>
    <org_study_id>15366</org_study_id>
    <secondary_id>I1V-MC-EIBN</secondary_id>
    <nct_id>NCT02161731</nct_id>
  </id_info>
  <brief_title>Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants</brief_title>
  <official_title>Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All study participants will receive both warfarin and a study drug called evacetrapib. The
      main purpose of this study is to look at how much warfarin gets into the blood stream and how
      long it takes the body to get rid of warfarin when given both with and without evacetrapib.
      Another purpose is to evaluate the effectiveness of warfarin therapy to prevent blood clots
      when given with evacetrapib by measuring the time it takes for blood to clot and comparing it
      to an average of the international normalized ratio (INR). INR measures the time it takes for
      blood to clot and compares it to an average.

      The study will last approximately 5 weeks, not including screening.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of S-Warfarin</measure>
    <time_frame>Days 1 and 17: 0, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours following warfarin dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Observed Concentration (Cmax) of S-warfarin</measure>
    <time_frame>Days 1 and 17: 0, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours following warfarin dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK: AUC[0-∞] of R-warfarin</measure>
    <time_frame>Days 1 and 17: 0, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours following warfarin dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of R-warfarin</measure>
    <time_frame>Days 1 and 17: 0, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours following warfarin dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Area Under the International Normalized Ratio Curve (AUC[INR]) of Warfarin</measure>
    <time_frame>Days 1 and 17: 0, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours following warfarin dose</time_frame>
    <description>The INR is a standardized ratio of the prothrombin time (PT), time it takes for blood to clot. AUC[INR] is the time curve used to measure change in INR over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Maximum Observed International Normalized Ratio Response (INRmax) of Warfarin</measure>
    <time_frame>Days 1 and 17: 0, 6, 12, 24, 36, 48, 72, 96, 120, and 144 hours following warfarin dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 milligram (mg) warfarin administered as a single oral dose on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evacetrapib + Warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evacetrapib administered once daily (QD), orally, for 16 days with 15 mg warfarin co-administered once orally on Day 17</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evacetrapib</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Evacetrapib + Warfarin</arm_group_label>
    <other_name>LY2484595</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Evacetrapib + Warfarin</arm_group_label>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants have given written informed consent approved by Lilly and the ethical
             review board (ERB) governing the site

          -  A medical history and physical examination consistent with a being a healthy
             individual

          -  Male participants will use a reliable method of birth control (as deemed by the
             investigator) and not donate sperm during the study and for 3 months following the
             last dose of the investigational product

          -  Female participants are not of child-bearing potential due to surgical sterilization
             (at least 6 weeks after surgical hysterectomy, bilateral oophorectomy, or tubal
             ligation) confirmed by medical history, or post-menopausal

          -  Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2)

          -  Participants are predicted to be cytochrome P450 2C9 (CYP2C9) extensive metabolizers
             as determined by genotyping assessment

        Exclusion Criteria:

          -  Have an abnormality in the 12-lead electrocardiogram (ECG) that increases the risks
             associated with participating in the study

          -  Have an abnormal supine blood pressure

          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data

          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human
             HIV antibodies

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody or evidence of
             hepatitis B and/or positive hepatitis B surface antigen

          -  Women who are pregnant or are lactating

          -  Have used or intend to use over-the-counter or prescription medications (including
             vitamins/mineral supplements, herbal medicine) 14 days prior to enrollment and during
             the study

          -  Have consumed grapefruit, cranberries, or grapefruit- or cranberry-containing products
             within 7 days prior to the first dose of warfarin

          -  Have a history or presence of significant bleeding disorders that is, hematemesis,
             melena, severe or recurrent epistaxis, hemoptysis, clinically overt hematuria or
             intracranial hemorrhage, gastrointestinal ulcers with hemorrhage

          -  Have a personal or family history of coagulation or bleeding disorders or reasonable
             suspicion of vascular malformations, for example, cerebral hemorrhage, aneurysm or
             premature stroke (cerebrovascular accident less than 65 years of age)

          -  Have a history of major head trauma (with loss of consciousness) within the past year
             or minor head trauma (without loss of consciousness) within the last 3 months prior to
             screening or history of major surgery within 3 months of screening

          -  Have planned surgery within 14 days after the last day of dosing

          -  Have an international normalized ratio/prothrombin time (INR/PT), or activated partial
             thromboplastin time (aPTT) above the normal reference range or abnormal Protein S
             antigen and/or Protein C activity at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <results_first_submitted>February 18, 2018</results_first_submitted>
  <results_first_submitted_qc>February 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 3, 2018</results_first_posted>
  <last_update_submitted>February 18, 2018</last_update_submitted>
  <last_update_submitted_qc>February 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Evacetrapib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Warfarin</title>
          <description>15 milligram (mg) warfarin administered as a single oral dose on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Evacetrapib + Warfarin</title>
          <description>Evacetrapib administered once daily (QD), orally, for 16 days on Days 7 - 22 with 15 mg warfarin co-administered once orally on Day 17.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (Day -1 to Day 7 Predose)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2 (Day 7 Dosing to Day 23)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Warfarin Then Evacetrapib + Warfarin</title>
          <description>15 mg warfarin administered as a single oral dose on Day 1. Evacetrapib administered QD, orally, for 16 days, Days 7- 22 with 15 mg warfarin co-administered once orally on Day 17.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.0" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of S-Warfarin</title>
        <time_frame>Days 1 and 17: 0, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours following warfarin dose</time_frame>
        <population>All participants who received a dose of study drug and had evaluable data for AUC [0-∞].</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>15 mg warfarin administered as a single oral dose on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Evacetrapib + Warfarin</title>
            <description>Evacetrapib administered QD, orally, for 16 days, Days 7 - 22 with 15 mg warfarin co-administered once orally on Day 17.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of S-Warfarin</title>
          <population>All participants who received a dose of study drug and had evaluable data for AUC [0-∞].</population>
          <units>nanogram*hour/milliliter (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" spread="23"/>
                    <measurement group_id="O2" value="114" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK: Maximum Observed Concentration (Cmax) of S-warfarin</title>
        <time_frame>Days 1 and 17: 0, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours following warfarin dose</time_frame>
        <population>All participants who received a dose of study drug and had evaluable data for Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>15 mg warfarin administered as a single oral dose on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Evacetrapib + Warfarin</title>
            <description>Evacetrapib administered QD, orally, for 16 days, Days 7 - 22 with 15 mg warfarin co-administered once orally on Day 17.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Maximum Observed Concentration (Cmax) of S-warfarin</title>
          <population>All participants who received a dose of study drug and had evaluable data for Cmax.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20" spread="21"/>
                    <measurement group_id="O2" value="4.34" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: AUC[0-∞] of R-warfarin</title>
        <time_frame>Days 1 and 17: 0, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours following warfarin dose</time_frame>
        <population>All participants who received a dose of study drug and had evaluable data for AUC[0-∞].</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>15 mg warfarin administered as a single oral dose on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Evacetrapib + Warfarin</title>
            <description>Evacetrapib administered QD, orally, for 16 days, Days 7 - 22 with 15 mg warfarin co-administered once orally on Day 17.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: AUC[0-∞] of R-warfarin</title>
          <population>All participants who received a dose of study drug and had evaluable data for AUC[0-∞].</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287" spread="16"/>
                    <measurement group_id="O2" value="271" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Cmax of R-warfarin</title>
        <time_frame>Days 1 and 17: 0, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours following warfarin dose</time_frame>
        <population>All participants who received a dose of study drug and had evaluable data for Cmax of R- enantiomers of Warfarin.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>15 mg warfarin administered as a single oral dose on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Evacetrapib + Warfarin</title>
            <description>Evacetrapib administered QD, orally, for 16 days, Days 7 - 22 with 15 mg warfarin co-administered once orally on Day 17.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Cmax of R-warfarin</title>
          <population>All participants who received a dose of study drug and had evaluable data for Cmax of R- enantiomers of Warfarin.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.03" spread="21"/>
                    <measurement group_id="O2" value="5.27" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics (PD): Area Under the International Normalized Ratio Curve (AUC[INR]) of Warfarin</title>
        <description>The INR is a standardized ratio of the prothrombin time (PT), time it takes for blood to clot. AUC[INR] is the time curve used to measure change in INR over time.</description>
        <time_frame>Days 1 and 17: 0, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 hours following warfarin dose</time_frame>
        <population>All participants who received a dose of study drug and had evaluable data for AUC[INR].</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>15 mg warfarin administered as a single oral dose on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Evacetrapib + Warfarin</title>
            <description>Evacetrapib administered QD, orally, for 16 days, Days 7 - 22 with 15 mg warfarin co-administered once orally on Day 17.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics (PD): Area Under the International Normalized Ratio Curve (AUC[INR]) of Warfarin</title>
          <description>The INR is a standardized ratio of the prothrombin time (PT), time it takes for blood to clot. AUC[INR] is the time curve used to measure change in INR over time.</description>
          <population>All participants who received a dose of study drug and had evaluable data for AUC[INR].</population>
          <units>ratio times hour (ratio*h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174" spread="7.0"/>
                    <measurement group_id="O2" value="165" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PD: Maximum Observed International Normalized Ratio Response (INRmax) of Warfarin</title>
        <time_frame>Days 1 and 17: 0, 6, 12, 24, 36, 48, 72, 96, 120, and 144 hours following warfarin dose</time_frame>
        <population>All participants who received a dose of study drug and had evaluable date for INRmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin</title>
            <description>15 mg warfarin administered as a single oral dose on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Evacetrapib + Warfarin</title>
            <description>Evacetrapib administered QD, orally, for 16 days, Days 7 - 22 with 15 mg warfarin co-administered once orally on Day 17.</description>
          </group>
        </group_list>
        <measure>
          <title>PD: Maximum Observed International Normalized Ratio Response (INRmax) of Warfarin</title>
          <population>All participants who received a dose of study drug and had evaluable date for INRmax.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="18"/>
                    <measurement group_id="O2" value="1.34" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>15 mg Warfarin</title>
          <description>15 milligram (mg) warfarin administered as a single oral dose on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>130 mg Evacetrapib</title>
          <description>130 mg Evacetrapib administered once daily (QD), orally, for 16 days, Days 7 - 22.</description>
        </group>
        <group group_id="E3">
          <title>15 mg Warfarin + 130 mg Evacetrapib</title>
          <description>Evacetrapib administered once daily (QD), orally, for 16 days, Days 7 - 22 with 15 milligram (mg) warfarin co-administered once orally on Day 17.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

